Clinical Trials Logo
  1. Home
  2. Myomectomy
  3. NCT04357015
  4. Details
NCT04357015 Clinical Trial

Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy

Myomectomy Clinical Trial

Official title:
Comparative Safety and Efficacy of Intravenous Tranexamic Acid Versus IV Carbetocin in Reducing Blood Loss During Abdominal Myomectomy: a Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04357015
Other study ID # tranexamic acid myomectomy
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2020
Est. completion date October 20, 2020

Study information
Verified date April 2020
Source Cairo University
Contact AHMED SAMY
Phone +201100681167
Email ahmedsamy8233@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 153
Est. completion date October 20, 2020
Est. primary completion date October 10, 2020
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging

Exclusion Criteria:

- women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• intravenous tranexamic acid
The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
• intravenous carbetocin
The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
• placebo
the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Cairo University

Outcome
Type Measure Description Time frame Safety issue
Primary intraoperative blood loss the intraoperative blood loss in ml will be estimated during the procedure one hour
Secondary need for blood transfusion need for intraoperative or postoperative blood transfusion 24 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04080375 - Preoperative Vaginal Dinoprostone Prior to Abdominal Myomectomy Phase 3
Completed NCT03634306 - Ultravision Visual Clearing System in Laparoscopic Hysterectomy and Myomectomy N/A
Completed NCT03308643 - Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Phase 4
Recruiting NCT03363425 - Effect of Perioperative iv Dexmedetomidine vs. Lidocaine on Postoperative Pain, Analgesic Consumption and Recovery After Abdominal Gynaecological Surgery Phase 2/Phase 3
Not yet recruiting NCT04358965 - Tranexamic Acid Versus Vaginal Misoprostol in Abdominal Myomectomy Phase 4
Completed NCT03250221 - Comparison of Robot-assisted Laparoscopic Myomectomy and Traditional Laparoscopic Myomectomy With Barbed Sutures
Completed NCT02741531 - The Effect of Partial Bladder Filling on Post-operative Time to Void in Minimally Invasive Gynecologic Procedures N/A
Completed NCT02049242 - Uterine Tourniquet at Open Myomectomy N/A
Completed NCT00978601 - Improved Recovery Using Multimodal Peri-operative Analgesia in Minimally Invasive Myomectomy N/A
Not yet recruiting NCT04357002 - Intravenous Tranexamic Acid Versus Vaginal Dinoprostone in Abdominal Myomectomy Phase 4
Completed NCT03892668 - Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy. Phase 4